Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery

Next Previous
Trial Profile

A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpha lactalbumin oleic acid (Primary) ; Epirubicin
  • Indications Bladder cancer
  • Focus Adverse reactions; Biomarker; First in man; Therapeutic Use
  • Sponsors Hamlet Pharma AB

    • Most Recent Events

    • 12 Jun 2023 According to a Hamlet Pharma AB media release, the company announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1.
    • 23 Feb 2023 According to a Hamlet Pharma AB media release, company is working closely with regulatory authorities, to move drug development closer to market approval.
    • 16 Aug 2022 According to a Hamlet Pharma AB media release, the Medicines Agency in the Czech Republic has approved application to amend the clinical trial for an extended Alpha1H in bladder cancer trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top